Candesartan - ≥99%, high purity , CAS No.139481-59-7, Antagonist of AT 1 receptor

Item Number

C129234

• Synonyms: candesartan | HTQMVQVXFRQIKW-UHFFFAOYSA-N | [3H]candesartan | CANDESARTAN CILEXETIL IMPURITY G [EP IMPURITY] | NCGC00167474-04 | C-266 | 1-[(2 inverted exclamation mark -(5-Tetrazolyl)-4-biphenylyl)methyl]-2-ethoxybenzimidazole-7-carboxylic Acid | BCPP000
• Specifications & Purity: Moligand™, ≥99%
• Biochemical and Physiological Mechanisms: Angiotensin II receptor 1 (AT1) antagonist (IC50values are 1.12 and 2.86 nM in bovine adrenal cortex and rabbit aorta, respectively). Exhibits antihypertensive effects in animal models. Also available as a prodrug,candesartan cilexetil.
• Storage Temp: Store at 2-8°C
• Shipped In: Wet ice
• Grade: Moligand™
• Action Type: ANTAGONIST
• Mechanism of action: Antagonist of AT 1 receptor
• Note: 10mg卖完停产，不再备货

Product Description

Candesartan is an angiotensin II receptor antagonist with IC50 of 0.26 nM.
A selective angiotensin II receptor antagonist.

Application：

CAN may be used as a pharmaceutical reference standard for the determination of the analyte in pharmaceutical formulations by spectrophotometric and chromatography techniques.These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

Candesartan is a selective AT1 (angiotensin II receptor 1) antagonist. Antagonism of angiotensin receptors inhibits vasoconstriction and the production of aldosterone, leading to a decrease in water and sodium concentration in blood plasma. Exhibits antihypertensive effects in animal models. Used in treatment of congestive heart failure, as antihypertensive. Candesartan does not affect cell viability or proliferation but increases the expression of VEGF and interleukin-8 in the cultured medium of KU-19-19 cells. Candesartan (0.1 nM) could reduce the maximal contractile response to angiostensin II by approximately 50%.